Jump to content

S-17092: Difference between revisions

Page 1
Page 2
Content deleted Content added
CheMoBot (talk | contribs)
Updating {{drugbox}} (changes to watched fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per [[Wikipedia:WikiProject Chemicals/Chembox validation|Chem/Drugbox valida
Importing Wikidata short description: "Chemical compound"
 
(24 intermediate revisions by 18 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{drugbox | Watchedfields = changed
{{drugbox
| verifiedrevid = 407869477
| Verifiedfields = changed
|
| Watchedfields = changed
| verifiedrevid = 415304348
| IUPAC_name = [(2S,3aS,7aS)-1([(R,R)-2-phenylcyclopropyl]-
| IUPAC_name = [(2S,3aS,7aS)-1([(R,R)-2-phenylcyclopropyl]-
carbonyl)-2-([thiazolidin-3-yl]carbonyl)octahydro-1H-indole
carbonyl)-2-([thiazolidin-3-yl]carbonyl)octahydro-1H-indole
| image = S-17092_structure_corrected.PNG‎
| image = S-17092.svg
| width = 240
| width = 250
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number =
| CAS_number =
| ATC_prefix =
| ATC_prefix =
| ATC_suffix =
| ATC_suffix =
| PubChem = 9977327
| PubChem = 9977327
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| DrugBank =
| UNII_Ref = {{fdacite|correct|FDA}}
| C = 23 | H = 29 | F = 1 | N = 2 | O = 2
| UNII = 8W5MLJ83KU
| molecular_weight = 384.486 g/mol
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| smiles = C5CCCN5C(=O)C1CC3CCCCC3N1C(=O)C2CC2c(cc4)ccc4F
| ChemSpiderID = 8152919
| smiles = O=C(N1CCCC1)[C@H]4N(C(=O)[C@H]3[C@H](c2ccc(F)cc2)C3)[C@H]5CCCC[C@H]5C4
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C23H29FN2O2/c24-17-9-7-15(8-10-17)18-14-19(18)22(27)26-20-6-2-1-5-16(20)13-21(26)23(28)25-11-3-4-12-25/h7-10,16,18-21H,1-6,11-14H2/t16-,18-,19+,20-,21-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = JNUXCIMICQKTPX-RQUKQETFSA-N
| C=23 | H=29 | F=1 | N=2 | O=2
| bioavailability =
| bioavailability =
| protein_bound =
| protein_bound =
<gallery>
File:Example.jpg|Caption1
File:Example.jpg|Caption2
</gallery>
| metabolism =
| metabolism =
| elimination_half-life =
| elimination_half-life =
| excretion =
| excretion =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU = <!-- A, B1, B2, B3, C, D, X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_US = <!-- A, B, C, D, X -->
| pregnancy_category=
| pregnancy_category=
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- Schedule I -->
| legal_CA = <!-- Schedule I -->
| legal_UK = <!-- Class A -->
| legal_UK = <!-- Class A -->
| legal_US =
| legal_US = Investigational New Drug
| legal_status = Investigational New Medicine
| legal_status =
| routes_of_administration =
| routes_of_administration =
}}
}}


'''S-17092''' is a drug which acts as a selective [[enzyme inhibition|inhibitor]] of the enzyme [[Prolyl endopeptidase]].<ref>Barelli H, Petit A, Hirsch E, Wilk S, De Nanteuil G, Morain P, Checler F. S 17092-1, a highly potent, specific and cell permeant inhibitor of human proline endopeptidase. ''Biochemical and Biophysical Research and Communications''. 1999 Apr 21;257(3):657-61. PMID 10208839</ref> This enzyme is involved in the metabolic breakdown of a number of [[neuropeptide]] [[neurotransmitter]]s in the brain,<ref>Bellemère G, Morain P, Vaudry H, Jégou S. Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance P and alpha-melanocyte-stimulating hormone breakdown in the rat brain. ''Journal of Neurochemistry''. 2003 Mar;84(5):919-29. {{DOI|10.1046/j.1471-4159.2003.01536.x}} PMID 12603817</ref><ref>Bellemère G, Vaudry H, Morain P, Jégou S. Effect of prolyl endopeptidase inhibition on arginine-vasopressin and thyrotrophin-releasing hormone catabolism in the rat brain. ''Journal of Neuroendocrinology''. 2005 May;17(5):306-13. PMID 15869566</ref> and so inhibiting the action of the enzyme increases the activity of these neuropeptides. This produces [[nootropic]] effects which make S-17092 a promising and novel treatment for neurodegenerative conditions such as [[Alzheimer's disease]] and [[Parkinson's disease]].<ref>Morain P, Lestage P, De Nanteuil G, Jochemsen R, Robin JL, Guez D, Boyer PA. S 17092: a prolyl endopeptidase inhibitor as a potential therapeutic drug for memory impairment. Preclinical and clinical studies. ''CNS Drug Reviews''. 2002 Spring;8(1):31-52. PMID 12070525</ref><ref>Morain P, Boeijinga PH, Demazières A, De Nanteuil G, Luthringer R. Psychotropic profile of S 17092, a prolyl endopeptidase inhibitor, using quantitative EEG in young healthy volunteers. ''Neuropsychobiology''. 2007;55(3-4):176-83. PMID 17700042</ref>
'''S-17092''' is a drug which acts as a selective [[enzyme inhibition|inhibitor]] of the enzyme [[prolyl endopeptidase]].<ref>{{cite journal | vauthors = Barelli H, Petit A, Hirsch E, Wilk S, De Nanteuil G, Morain P, Checler F | title = S 17092-1, a highly potent, specific and cell permeant inhibitor of human proline endopeptidase | journal = Biochemical and Biophysical Research Communications | volume = 257 | issue = 3 | pages = 657–61 | date = April 1999 | pmid = 10208839 | doi = 10.1006/bbrc.1999.0366 }}</ref> This enzyme is involved in the metabolic breakdown of a number of [[neuropeptide]] [[neurotransmitter]]s in the brain,<ref>{{cite journal | vauthors = Bellemère G, Morain P, Vaudry H, Jégou S | title = Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance P and alpha-melanocyte-stimulating hormone breakdown in the rat brain | journal = Journal of Neurochemistry | volume = 84 | issue = 5 | pages = 919–29 | date = March 2003 | pmid = 12603817 | doi = 10.1046/j.1471-4159.2003.01536.x | s2cid = 24773419 }}</ref><ref>{{cite journal | vauthors = Bellemère G, Vaudry H, Morain P, Jégou S | title = Effect of prolyl endopeptidase inhibition on arginine-vasopressin and thyrotrophin-releasing hormone catabolism in the rat brain | journal = Journal of Neuroendocrinology | volume = 17 | issue = 5 | pages = 306–13 | date = May 2005 | pmid = 15869566 | doi = 10.1111/j.1365-2826.2005.01308.x | s2cid = 9129184 }}</ref> and so inhibiting the action of the enzyme increases the activity of these neuropeptides. This produces [[nootropic]] effects which make S-17092 a promising and novel treatment for neurodegenerative conditions such as [[Alzheimer's disease]] and [[Parkinson's disease]].<ref>{{cite journal | vauthors = Morain P, Lestage P, De Nanteuil G, Jochemsen R, Robin JL, Guez D, Boyer PA | title = S 17092: a prolyl endopeptidase inhibitor as a potential therapeutic drug for memory impairment. Preclinical and clinical studies | journal = CNS Drug Reviews | volume = 8 | issue = 1 | pages = 31–52 | pmid = 12070525 | pmc = 6741683 | year = 2002 | doi = 10.1111/j.1527-3458.2002.tb00214.x }}</ref><ref>{{cite journal | vauthors = Morain P, Boeijinga PH, Demazières A, De Nanteuil G, Luthringer R | title = Psychotropic profile of S 17092, a prolyl endopeptidase inhibitor, using quantitative EEG in young healthy volunteers | journal = Neuropsychobiology | volume = 55 | issue = 3–4 | pages = 176–83 | pmid = 17700042 | doi = 10.1159/000107070 | year = 2007 | s2cid = 27856130 }}</ref>


==See also==
== See also ==
* [[C16 (PKR inhibitor)]]
* [[UK-414,495]]
* [[UK-414,495]]


==References==
== References ==
{{reflist}}
{{reflist}}


[[Category:Hydrolase inhibitors]]

{{Psychostimulants, agents used for ADHD and nootropics}}

[[Category:Enzyme inhibitors]]
[[Category:Nootropics]]
[[Category:Nootropics]]
[[Category:Amides]]
[[Category:Carboxamides]]
[[Category:Indoles]]
[[Category:Indoles]]
[[Category:Thiazolidines]]
[[Category:Thiazolidines]]